Clinical Trial ResultsPositive early data seen in triple-negative breast cancer study with paxalisib, showing significant reductions in circulating tumor cells.
Financial StabilityThe breast cancer study is funded by investigators and does not require capital investments from Kazia, which is beneficial for the company's financial stability.
Safety ProfileNo unexpected safety signals were seen with the low dose of paxalisib, which is viewed as a positive signal.